Hepatorenal syndrome: A review

Hepato-Gastroenterology

Volumn 57, Issue 102-103, 2010, Pages 1279-1284

  Testino, Gianni ^a   Ferro, Carlo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Ascites; Cirrhosis; Dilutional hyponatriemia; Hepatorenal syndrome; Liver transplantation; Model of end stage liver disease; Portal hypertension; Spontaneous bacterial peritonitis; Transjugular intrahepatic portosystemic stent shunt

Indexed keywords

ALBUMIN; FUROSEMIDE; MIDAZOLAM; MIDODRINE; NORADRENALIN; NORFLOXACIN; OCTREOTIDE; PENTOXIFYLLINE; PETHIDINE; SPIRONOLACTONE; TERLIPRESSIN;

ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ARTERIAL BLOOD; ASCITES; BACTERIAL PERITONITIS; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; KIDNEY PERFUSION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; PERFUSION PRESSURE; PRIORITY JOURNAL; REVIEW; SODIUM EXCRETION; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT DURATION; TREATMENT RESPONSE; URINE VOLUME; VASOCONSTRICTION;

HEPATORENAL SYNDROME; HUMANS; LIVER TRANSPLANTATION; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC;

EID: 79251569583     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Iwatsuki S, Popovtzer MM, Corman JL: Recovery from "hepatorenal syndrome" after orthotopic liver transplantation. N Eng J Med 1973; 289:1155-1159.
2. Arroyo V, Planas R, Gaya J: Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 1983; 13:271-278. (Pubitemid 13100449)
3. Genzini T, Torricelli FCM: Hepatorenal syndrome: an update. Sao Paulo Med J 2007; 125:50-56.
4. Arroyo V, Gines P, Gerbers AL, Dudley FJ, Gentilizi P, Laffi G, Reynolds TB, Ring-Larsen H, Scholmerich J: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23:164-176.
5. Ng CKF, Chan MHM, Tai MHL, Lam CWK: Hepatorenal syndrome. Clin Biochem Rev 2007; 28:11-17.
6. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56:1310-1318.
7. Wadei HM, Mai ML, Ahsan N, Gonwa TA: Hepatorenal syndrome: pathophysiology and management. Clin J Am Soc Nephrol 2006; 1:1066-1079.
8. Arroyo V, Fernandez J, Gines P: Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008; 28:81-95.
9. Fasolato S, Angeli P, Dallagnese L: Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007; 45:223-229.
10. Munoz SJ: The hepatorenal syndrome. Med Clin N Am 2008; 92:813-837.
11. Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B, Valente U: Type-2 hepatorenal syndrome and refractory ascites: role of transjugular portosystemic stent shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation. Hepatogastroenterology 2003; 50:1169-1171.
12. Wong F: Hepatorenal syndrome: current management. Current Gastroenterology Report 2008; 10:22-29.
13. Ruiz-del-Arbol L, Monescillo A, Arocena C: Ciurculatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42:439-447. (Pubitemid 41061097)
14. Lee SS, Liu H: Cardiovascular determinants of survival in cirrhosis. Gut 2007; 56:746-748.
15. Iwakiri Y, Groszmann R: The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006; 43:S121-S131.
16. Riordan SM, Williams R: The intestinal flora and bacterial infection in cirrhosis. J Hepatol 2006; 45:744-757.
17. Ming Z, Smyth DD, Lautt WW: Decreases in portal flow trigger a hepatorenal reflex to inhibit renal sodium and water excretion in rats: role of adenosine. Hepatology 2002; 35:167-175.
18. Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jiemenez V, Arroyo V, Rodes J, Gines P: MELD score and clinical type predict prognosis in hepatorenal sindrome: relevance to liver transplantation. Hepatology 2005; 41:1282-1289.
19. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA: Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41:32-39.
20. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG: Addition of serum sodium into MELD score predicts waiting list mortality better than MELD alone. Liver Transplantation 2005; 3:336-343.
21. Heuman DM, Abou-assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, Fisher RA, Mihas AA: Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40:802-810.
22. Londono MC, Guevara M, Rimola A, Navasa M, Taura P, Mas A, Arroyo V, Gines P: Hyponatriemia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006; 130:1135-1143.
23. Sumberaz A, Centenaro M, Ansaldi F, Ancarani AO, Andorno E, Testino G: Relationship between laboratori parameters and intensive care unit stay post-liver transplantation: proposal of a model. Transplant Proc 2007; 39:1868-1870.
24. Testino G: Alcoholic diseases in hepato-gastroenterology: a point of view. Hepatogastroenterology 2008; 55:371-377.
25. Cardenas A, Gines P: Management of complications of cirrhosis in patients awaiting liver transplantation. J of Hepatol 2005; 42:S124-S133.
26. Fernandez J, Navasa M, Planas R: Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133:818-824.
27. Alessandria C, Ottobrelli A, Debernardi-Venon W: Noradrenaline vs terlipressin in patients with hepatorenal syndrome: a prospective randomized unblinded pilot study. J Hepatol 2007; 47:499-505.
28. Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Ozdil S, Kaimakoglu S, Okten A: Terlipressin and albumin combination treatment in hepatorenal syndrome. Hepatogastroenterology 2003; 50 Suppl 2:305-308.
29. Estrailian E, Pantangco ER, Kyulo NL: Octreotide/ midodrine therapy significantly improves renal function and 30-day survival in patients with type-1 hepatorenal syndrome. Dig Dis Sci 2007; 52:742-748. (Pubitemid 46303050)
30. Restuccia T, Ortega R, Guevara M, Gines P, Alessandria C, Arroyo V, Rodes J: Effects of treatments of hepatorenal syndrome before transplantation on post-transplantation outcome. A case-control study. J of Hepatol 2004; 40:140-146.
31. Lerut J, Goffette P, Laterre PF, Donataccio M, Reynaert MS, Otte JB: Sequential treatment of hepatorenal syndrome and posthepatic cirrhosis by Intrahepatic portosystemic shunt and liver transplantation. Hepatogastroenterology 1995; 42:985-987.
32. Boyer TD: Transjugular Intrahepatic portosystemic shunt in the management of complications of portal hypertension. Current Gastroenterology Reports 2008; 10:30-35.
33. Senzolo M, Cholongitas E, Tibbals J, Burroughs A, Patch D: Transjugular Intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome. Eur J Gastroenterol Hepatol 2006; 18:1143-1150. (Pubitemid 44563871)
34. Testino G, Ferro C: Type-1 hepatorenal syndrome in patients with alcoholic end stage liver disease listed for liver transplantation: role of transjugular intrahepatic portosystemic stent shunt. Panminerva Med 2007; 49:43-45.
35. Runyon BA: Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49:2087-2107.